Early action is key.
Empowering patients to better protect themselves from severe allergic reactions that could lead to anaphylaxis. Anaphylaxis is a severe, life-threatening allergic reaction that can occur very quickly — as fast as within a couple of minutes — and could be fatal if not treated immediately.
An Alternative to Epinephrine
We are developing ARS-1, an epinephrine nasal spray that could transform the treatment of severe allergic reactions that may lead to anaphylaxis for patients and their families.
Some people may take a “watch and wait” approach to using an auto-injector. Oftentimes, delaying an injection can result in the allergic reaction progressing to anaphylaxis and emergency situations. ARS-1 may enable easy delivery of epinephrine to treat severe allergic reactions more rapidly and with less hesitation.
There is a fear of needles and stigma that leads to an unwillingness to use an auto-injector in public to treat severe allergic reactions. For parents or guardians, injecting a child may also be traumatic.
ARS-1 is uniquely formulated with an absorption enhancing technology that has shown a comparable rate of epinephrine absorption to intramuscular injection with less risk of variability.
Small enough to carry in a pocket or purse anytime, anywhere.